News stories about OncoMed Pharmaceuticals (NASDAQ:OMED) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoMed Pharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.279441013333 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of OncoMed Pharmaceuticals (NASDAQ:OMED) traded up 1.33% during mid-day trading on Thursday, reaching $3.82. The company had a trading volume of 82,969 shares. The stock has a 50 day moving average of $4.47 and a 200-day moving average of $4.11. The firm’s market capitalization is $143.75 million. OncoMed Pharmaceuticals has a one year low of $2.91 and a one year high of $10.89.
OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. The business had revenue of $6.20 million during the quarter, compared to the consensus estimate of $6.08 million. During the same period in the prior year, the firm earned ($0.91) EPS. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. Equities analysts predict that OncoMed Pharmaceuticals will post ($1.85) EPS for the current year.
A number of research analysts have commented on OMED shares. Jefferies Group LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of OncoMed Pharmaceuticals in a research report on Sunday, July 9th. Zacks Investment Research lowered OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. SunTrust Banks, Inc. restated a “hold” rating and issued a $4.00 price target on shares of OncoMed Pharmaceuticals in a research report on Friday, October 6th. Cantor Fitzgerald restated a “hold” rating and issued a $6.00 price target on shares of OncoMed Pharmaceuticals in a research report on Tuesday, September 19th. Finally, Piper Jaffray Companies set a $5.00 price target on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $5.84.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.